Overexpression of MRPs (such as MRP1, MRP2, and MRP3), and high NRF2 activity enhance drug efflux in these cancers, leading to chemoresistance and poor response to treatments by effectively removing chemotherapy agents from cancer cells (22, 82). Here, NFE2L2 is linked to cancer.